Verslype C, Carton S, Borbath I, Delaunoit T, Demetter P, Demolin G, Hendlisz A, Pattyn P, Pauwels S, Peeters M, Roeyen G, Van Hootegem Ph, Van Laethem J L, Van Cutsem E
Department of Hepatology and Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium.
Acta Gastroenterol Belg. 2009 Jan-Mar;72(1):54-8.
Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP NETs). These compounds can control the symptoms induced by the production of hormones and peptides. The antiproliferative effects of SSAs and especially tumour shrinkage are less obvious in patients with GEP NETs than in those with acromegaly. However, based upon phase II experience there is a strong suggestion of a disease stabilizing effect of SSAs in selected patients. Those patients with a progressive, non-functional GEP NET, positive octreotide scintigraphy, a low proliferation index and in the absence of surgical options may benefit from a first-line medical therapy with SSAs. The exploration of the mechanisms of this effect are unclear and hampered by the lack of suitable preclinical models. The better understanding of the tumour biology of GEP NETs, together with the development of new SSAs with better affinity on all somatostatin receptors, represent an unmet medical need.
生长抑素类似物（SSAs）在胃肠道和胰腺神经内分泌肿瘤（GEP NETs）患者的管理中发挥着重要作用。这些化合物可以控制激素和肽产生所引发的症状。与肢端肥大症患者相比，SSAs的抗增殖作用，尤其是肿瘤缩小作用在GEP NETs患者中不太明显。然而，根据II期试验经验，强烈提示SSAs在部分患者中具有疾病稳定作用。那些患有进展性、无功能GEP NET、奥曲肽闪烁扫描阳性、增殖指数低且没有手术选择的患者可能从一线使用SSAs的药物治疗中获益。这种作用机制尚不清楚，且由于缺乏合适的临床前模型而受到阻碍。更好地了解GEP NETs的肿瘤生物学，以及开发对所有生长抑素受体具有更高亲和力的新型SSAs，是尚未满足的医学需求。
